Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
Fiche publication
Date publication
janvier 2021
Journal
Breast (Edinburgh, Scotland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr HENNEQUIN Audrey
Tous les auteurs :
Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De la Motte Rouge T, Laborde L, Laurent C, Chamorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Lerebours F
Lien Pubmed
Résumé
Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains uncertain. The purpose of this study was to identify predictive factors of outcome after third- or fourth-line chemotherapy.
Mots clés
Chemotherapy, Heavily pretreated, Metastatic breast cancer, Prognostic factors, Real-life
Référence
Breast. 2021 Jan 30;56:18-25